Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 3
1993 1
1994 1
1999 3
2001 2
2002 1
2003 1
2006 3
2007 1
2008 2
2009 3
2010 2
2011 2
2012 1
2013 1
2014 1
2020 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Pappa KA, Curtis L, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B. Cahn P, et al. Among authors: pappa ka. AIDS. 2022 Jan 1;36(1):39-48. doi: 10.1097/QAD.0000000000003070. AIDS. 2022. PMID: 34534138 Free PMC article. Clinical Trial.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY. Osiyemi O, et al. Among authors: pappa ka. Clin Infect Dis. 2022 Sep 29;75(6):975-986. doi: 10.1093/cid/ciac036. Clin Infect Dis. 2022. PMID: 35079789 Free PMC article. Clinical Trial.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. Among authors: pappa ka. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
The clinical development of mupirocin.
Pappa KA. Pappa KA. J Am Acad Dermatol. 1990 May;22(5 Pt 1):873-9. doi: 10.1016/0190-9622(90)70116-y. J Am Acad Dermatol. 1990. PMID: 2112164 Review.
Pharmacokinetics of oral and transdermal triprolidine.
Miles MV, Balasubramanian R, Pittman AW, Grossman SH, Pappa KA, Smith MF, Wargin WA, Findlay JW, Poust RI, Frosolono MF. Miles MV, et al. Among authors: pappa ka. J Clin Pharmacol. 1990 Jun;30(6):572-5. doi: 10.1002/j.1552-4604.1990.tb03623.x. J Clin Pharmacol. 1990. PMID: 2355108
Low-dose ranitidine for the relief of heartburn.
Pappa KA, Gooch WM, Buaron K, Payne JE, Giefer EE, Sirgo MA, Ciociola AA. Pappa KA, et al. Aliment Pharmacol Ther. 1999 Apr;13(4):459-65. doi: 10.1046/j.1365-2036.1999.00507.x. Aliment Pharmacol Ther. 1999. PMID: 10215729 Free article. Clinical Trial.
Comment: topical mupirocin.
Pappa KA. Pappa KA. Drug Intell Clin Pharm. 1987 May;21(5):466. doi: 10.1177/106002808702100520. Drug Intell Clin Pharm. 1987. PMID: 3107962 Clinical Trial. No abstract available.
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Eron J, Hung CC, Baril JG, Slim J, Falcó V, Bogner J, Maggiolo F, Mills A, Sievers J, Man CY, Urbaityte R, Underwood M, Tenorio AR, Pappa KA, Wynne B, Koteff J, Gartland M, Smith KY, Aboud M. Eron J, et al. Among authors: pappa ka. J Acquir Immune Defic Syndr. 2020 May 1;84(1):60-65. doi: 10.1097/QAI.0000000000002302. J Acquir Immune Defic Syndr. 2020. PMID: 31977595 Clinical Trial.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY. van Wyk J, et al. Among authors: pappa ka. Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. doi: 10.1093/cid/ciz1243. Clin Infect Dis. 2020. PMID: 31905383 Free PMC article. Clinical Trial.
32 results